India RA Market Outlook to 2028

India RA Market Overview

The India RA (Rheumatoid Arthritis) market is valued at INR 12.8 billion, based on a five-year historical analysis. The market size is primarily driven by the increasing prevalence of RA among the aging population and growing awareness about early diagnosis and treatment options. Additionally, advancements in biologic therapies and government support through health schemes further push the markets growth trajectory.

The RA market is dominated by cities like Mumbai, Delhi, and Bangalore due to their advanced healthcare infrastructure, availability of specialized rheumatology centers, and access to innovative treatments like biologics. These cities also benefit from a high concentration of specialists and well-established pharmaceutical supply chains, facilitating better treatment accessibility and delivery.

The Indian governments initiatives, such as the National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases & Stroke (NPCDCS), are critical for managing chronic conditions like RA. In 2024, the program received USD 1.5 billion in funding, with a substantial portion dedicated to chronic disease management. This initiative has enabled better early diagnosis, preventive care, and management of RA in both urban and rural settings. Healthcare facilities under this scheme cater to millions of RA patients across the country.

India RA Market Segmentation

By Drug Class: The India RA market is segmented by drug class into biologics, DMARDs (Disease Modifying Anti-Rheumatic Drugs), NSAIDs, and corticosteroids. Among these, biologics have emerged as the dominant segment. The prominence of biologics in the Indian RA market stems from their targeted approach in inhibiting specific pathways involved in the disease process, leading to better patient outcomes. Moreover, the introduction of biosimilars, which offer cost-effective alternatives to expensive biologics, has contributed to their increased uptake across the country.

By Distribution Channel: The distribution of RA treatments is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies hold the dominant market share due to the complex nature of RA treatments, which often require specialized handling and administration. Additionally, biologic drugs, which are often injected, are commonly dispensed through hospital networks to ensure proper administration under medical supervision.

Competitive Landscape

The India RA market is consolidated with key pharmaceutical players dominating the market. The major companies leverage extensive distribution networks, strong research and development pipelines, and strategic partnerships with international brands. The India RA market is dominated by a few major players, including Sun Pharmaceuticals, Cipla, and Dr. Reddys Laboratories, which have strong research and development capabilities and broad distribution networks. Their dominance is further enhanced by their ability to navigate regulatory pathways efficiently and offer innovative treatment options such as biologics and biosimilars.

Company

Year Established

Headquarters

Drug Portfolio

Market Reach

R&D Investments

Regulatory Approvals

Therapeutic Focus

Collaborations

Sun Pharmaceuticals

1983

Mumbai, India

Cipla Ltd.

1935

Mumbai, India

Lupin Limited

1968

Mumbai, India

Dr. Reddys Laboratories

1984

Hyderabad, India

Torrent Pharmaceuticals

1959

Ahmedabad, India

India RA Market Analysis

Growth Drivers

Aging Population and Increased Incidence of RA: India's aging population is a significant driver for the rise in rheumatoid arthritis (RA). In 2024, approximately 139 million people in India are aged 60 or above, a demographic heavily prone to chronic conditions like RA. The prevalence of RA in India is around 0.75% of the total population, affecting nearly 10 million people. This has led to increased healthcare demands and challenges in managing chronic illnesses. The World Bank notes that India's population over 60 years is expected to grow by 41% by 2031, further stressing healthcare infrastructure.

Increasing Healthcare Spending (Healthcare Expenditure % of GDP): Indias healthcare spending has been rising steadily, contributing to better RA care. In 2024, India is projected to spend approximately USD 88 billion on healthcare, with healthcare expenditure representing around 3.5% of the GDP. This increase supports the expansion of healthcare infrastructure, diagnosis, and treatment capabilities, especially for chronic diseases like RA. Government health schemes such as Ayushman Bharat also play a critical role in providing access to RA treatments across both urban and rural regions.

Advancements in Biologics and Biosimilars (Biologics Market Contribution): India has witnessed a significant rise in the availability and use of biologics and biosimilars to treat RA. In 2024, biologics contribute over USD 1.2 billion to India's overall pharmaceuticals market. Several key biologics have received regulatory approval in India, enhancing treatment options for RA patients. The increase in biosimilar manufacturing capabilities in India, backed by government incentives for biotechnology research, ensures broader access to these advanced treatments, helping reduce the disease burden.

Market Challenges

High Cost of RA Treatments (Cost Analysis): RA treatments, particularly biologics, are expensive, making them inaccessible to a large portion of the Indian population. The average annual cost of RA biologic treatment in India can range between INR 100,000 to INR 200,000 in 2024, depending on the severity and required medication. Although government schemes provide some relief, a vast majority of patients in rural areas remain underserved due to high out-of-pocket expenses. This high cost continues to be a significant barrier to widespread RA treatment access.

Lack of Early Diagnosis (Patient Access to Diagnosis Rates): The lack of early diagnosis in RA remains a persistent challenge in India. In 2024, it is estimated that only 35% of RA patients receive a diagnosis within the first year of symptom onset, leading to delayed treatment and worsened outcomes. Diagnostic infrastructure, especially in rural areas, is insufficient, with less than 20% of rural patients having access to proper diagnostic facilities. The government has been working to improve access to diagnostic services, but it remains a slow process.

Future Outlook

Over the next few years, the India RA market is expected to experience substantial growth driven by a combination of factors, including the introduction of new biologic therapies, improved patient access to treatment, and a growing elderly population. Government initiatives to improve healthcare access in rural areas and advancements in personalized medicine are also set to fuel market expansion. The increasing prevalence of lifestyle diseases and autoimmune disorders, including rheumatoid arthritis, will necessitate ongoing innovation in drug development and delivery.

Market Opportunities

Growth of Telemedicine for RA Care (Telemedicine Adoption Rate): Telemedicine has grown as a vital tool in RA care, especially in remote regions. In 2024, India recorded more than 150 million telemedicine consultations, driven by government initiatives and private healthcare platforms. Telemedicine allows RA patients in rural and semi-urban areas to access specialist consultations without the need to travel, helping bridge the healthcare accessibility gap. Government regulations on telemedicine, introduced in 2020, have accelerated the growth of this sector, creating opportunities for improved RA management across the country.

Expansion of Private Health Insurance (Insurance Penetration): The expansion of private health insurance in India has created more opportunities for RA patients to access expensive treatments like biologics. In 2024, more than 520 million Indians are covered under private or government-backed health insurance schemes, a significant increase from 450 million in 2022. Private insurance plans are increasingly offering coverage for chronic diseases, including RA, which helps alleviate the financial burden of treatment. The growing insurance penetration is expected to boost access to RA care.
Please Note: It will take 5-7 business days to complete the report upon order confirmation Show more